

ENSCCA / PRECISION-BTC- NETWORK JOINT MEETING

July 1 - 2, 2024

Krakow,
Poland



WELCOME FROM THE ORGANIZERS

It is our great pleasure to welcome you to 4th biennial ENSCCA Meeting, held in conjunction with the Precision-BTC-Network COST Action in the beautiful and historic city of Krakow.

Key to the planning and organization of this event has been a focus on fostering collaboration and sharing cutting-edge knowledge. The meeting agenda is full of interesting presentations by prominent speakers with diverse specialties and backgrounds, which cover this meeting's six session topics: Characterization of BTC, Personalizing Early Diagnosis, Precision Therapeutic Strategies, Patient-centric Approach, Artificial Intelligence to Guide BTC Treatment, and New Preclinical Models.

We have also been keen on providing a platform for emerging talent. Young researchers working in the field of biliary cancer will participate in the meeting sessions giving talks and collaborating as moderators; as well as in the meeting's poster session, where they will have the opportunity to share their original research with their fellow attendees.

It is our hope that this poster session—and that the conference generally—will serve as a forum for networking and relationship building. It is through shared effort involving a range of stakeholders from different backgrounds that we best address the challenges related to the prevention, detection and treatment of BTC.

As a final point, we would like to extend our sincere gratitude to all those who have contributed to making this meeting a reality. This important event would not have been possible without the generous support of our sponsors and collaborators. Thank you.

With our best wishes for a fruitful and rewarding meeting,

The organization team





ENSCCA / Precision-BTC-Network Joint Meeting

July 1st - 2nd, 2024

Jagiellonian University,
Faculty of Law & Administration
Krupnicza 33A, Krakow, PL

July 1st

TIME (CEST)	TITLE	SPEAKER
08:00-08:45	REGISTRATION	
08:45-9:00	WELCOME from the ENSCCA/COST WELCOME from the local committee	C. Braconi / R. Macias J. Kotlinowski
9:00-10:45	Update on Biliary Tract Cancers (in partnership with ENSCCA/ILCA/EASL/ESMO)	
	<i>CHAIRS</i>	L. Rimassa / A. Saborowski
09:00-09:10	CCA: A brief overview	S. Roessler
09:10-09:25	Role of Endoscopy in Diagnosis and Treatment of Biliary Cancers	L. Krupa
09:25-09:40	Immunotherapy in BTC	A. Vogel
09:40-09:55	Local Therapies for Biliary Cancer: Are we there yet?	J. Edeline
09:55-10:10	BTC: A disease for personalized targeted therapies	T. Macarulla
10:10-10:35	PANEL DISCUSSION (with the addition of)	T. Kendall
10:35-10:50	COFFEE BREAK	
10:50-11:15	Presentation of the ENSCCA / ICRN / Precision-BTC consensus	C. Braconi / J. Valle
11:15-11:25	Experience from Previous COST Action: The example of Euro-Cholangio-Net	V. Cardinale
11:30-13:00	BTC Characterization through a Pan-European Collaborative Effort	
	<i>CHAIRS</i>	V. Cardinale / M. Afonso
11:30-11:45	European Clinical Registry: Where we are and where we are going	J. Banales / L. Izquierdo
11:45-12:00	European Morphological Registry of Cholangiocarcinoma: An update	G. Carpino / T. Kendall
12:00-12:15	International Registry on Gallbladder Cancer	M. Krawczyk
12:15-12:25	Ampullary Lesions: Considerations for an international registry	M. Hollenbach
12:25-12:35	<i>Gold Award recipient</i> : Refinement of histologic subtypes and identification of biomarkers linked to unfavourable prognosis in CCA	D. Overi
12:35-13:00	PANEL DISCUSSION (with the addition of)	A. Lamarca / C. Gabbi / M. Cornillet
13:00-14:00	LUNCH	
14:00-15:30	Personalizing the Early Diagnosis of Biliary Cancer	
	<i>CHAIRS</i>	S. Roessler / C. Gabbi
14:00-14:15	Patients at Risk: Learning about primary sclerosing cholangitis	C. Schramm
14:15-14:30	Novel Biomarkers for Early Diagnosis: The role of metabolomics	P. Rodrigues
14:30-14:45	Novel Pre-clinical Models to Study the Evolution from PSC to CCA	L. Boulter
14:45-14:55	The Asp-PSC-Trial: A platform for translational analyses in early diagnosis	S. Khan
14:55-15:05	International Consortium for the Genetics of Biliary Tract Cancers: A cholangiocarcinoma GWAS study	L.R. Roberts
15:05-15:30	PANEL DISCUSSION (with the addition of)	J. Banales / A. Forner
15:30-15:45	BREAK & GROUP PHOTO	
15:45-17:15	Precision Therapeutic Strategies in Biliary Tract Cancers	
	<i>CHAIRS</i>	A. Lamarca / P. Olthof
15:45-16:00	Neoadjuvant Treatment in BTC	L. Rimassa
16:00-16:15	Identifying the Correct Candidates: The definition of resectable disease	G. Sapisochin
16:15-16:30	Identifying the Correct Candidates: Can molecular biology help?	C. O'Rourke
16:30-16:40	Immune and Molecular Profiling of Biliary Tract Cancer Treated with First-line Chemo-immunotherapy	R. Balsano
16:40-16:50	Circular RNAs in Cholangiocarcinoma: Mechanisms and biomarkers (a brief overview)	C. Coulouarn
16:50-17:15	PANEL DISCUSSION (with the addition of)	J. Primrose / A. Vogel
17:15-18:45	Poster Session and Presentation of Silver Award Recipients	Poster tour (A. Landa / E. Jarman)
17:15-18:45	Precision-BTC-Net Management Committee Meeting (Invite Only)	

July 2nd

TIME	TITLE	SPEAKER
08:45-9:00	WELCOME from the local committee	J. Kotlinowski / M. Krawczyk
9:00-10:30	A Patient-Centric Approach	
	<i>CHAIRS</i>	A. Forner / C. Braconi
09:00-09:15	Development of Patients' Contents: The AMMF experience	H. Morement
09:15-09:30	How to Start a Patients' Charity: The Spanish experience	E. Baucells Molera
09:30-09:45	Sustainable Future of a Patients' Charity: The Italian experience	P. Leonardi
09:45-10:00	The Interaction of Patients' Charity with Pharma and Regulatory Bodies: The CCF experience	S. Lindsey
10:00-10:10	The Quality of Life in Biliary Tract Cancer Patients: The current state and where we are headed	L. Cavka
10:10-10:35	PANEL DISCUSSION (with the addition of)	P. Martin / G. Iserte
10:35-11:00	COFFEE BREAK	
11:00-12:30	The Potential of Artificial Intelligence in Guiding BTC Management	
	<i>CHAIRS</i>	J. Andersen / L. Fabris
11:00-11:15	European Molecular Registry of Cholangiocarcinoma: An update	J. Andersen
11:15-11:30	Artificial Intelligence for Clinical Cancer Research: Past, present, future	H. Muti
11:30-11:45	Integrating Digital Pathology and Spatial Genomics in Liver Cancer	S. Caruso
11:45-11:55	Radiomics in Intrahepatic Cholangiocarcinoma: Bridging gaps from data to evidence	L. Viganò
11:55-12:05	Application of AI in Early Diagnosis	S. Pereira
12:05-12:30	PANEL DISCUSSION (with the addition of)	B. Goepfert
12:30-13:00	ORAL PRESENTATIONS from Submitted Abstracts	
	<i>CHAIRS</i>	P. Acedo / R. Macias
	<i>Gold Award recipient:</i> The consequences of losing primary cilia in Intrahepatic Cholangiocarcinoma	S. Teles
	<i>Gold Award recipient:</i> Monocytes contribution to chemoresistance in biliary tract cancers	F. Amato
	<i>Gold Award recipient:</i> Specific inhibition of PARP-1 preferentially impairs KRAS-mutated iCCA and is mediated by CHK1 kinase	D. Castven
13:00-14:00	LUNCH	
14:00-15:30	Novel Pre-clinical Models to Support Drug Development	
	<i>CHAIRS</i>	M. Verstagen / T. Tian
14:00-14:15	Mcpip1 Knockout Mice as a New Model to Study Ductular Reaction	J. Kotlinowski
14:15-14:30	Modulating WNT/ β -Catenin Pathway Activity as a Chemosensitive Strategy in Cholangiocarcinoma	E. Lozano
14:30-14:45	Exploiting CAF for Treatment in Cholangiocarcinoma	S. Marco
14:45-14:55	Using Patient-led Genetics to Identify New Metastatic Drivers in Cholangiocarcinoma	P. Olaizola
14:55-15:05	Syngeneic Ectopic Mouse Model of Cholangiocarcinoma to Test Innovative Physics-based Local Therapies	L. Fouassier
15:05-15:15	Novel Chemotherapeutic Agents in Biliary Cancer	F. Cossio
15:15-15:40	DISCUSSION (with the addition of)	C. Athanassopoulos / L. Boulter
15:40-16:00	CONCLUSIONS	



MEETING SPONSORS AND COLLABORATORS



SPONSORS



LKB Biotech



European Network for the Study of Cholangiocarcinoma



JAGIELLONIAN UNIVERSITY IN KRAKÓW

ORGANIZERS & COLLABORATORS



VNIVERSIDAD B SALAMANCA

endorsed by



EASL

Endorsed

SELECTED ABSTRACTS

The following abstracts have been selected by the ENSCCA/Precision-BTC-Network Joint Meeting abstract selection committee for Gold, Silver Special Recognition, Silver, & Bronze Awards. The name of the presenting author is underlined.

Abstract Title	Authors	Award
<i>Monocytes Contribution to Chemoresistance in Biliary Tract Cancers</i>	<u>E Amato</u> , J Greaves, F Vita, I Olaizola Rebe, C O'Rourke, M Ruiz de Gauna, P Sanchon-Sanchez, L McGarry, M McLeod, C Rae, S Marco Martin, S Puttagunta, B Liu, G Armstrong, K Allan, A MacMillian, O Knight, J Andersen, C Braconi	Gold
<i>Specific inhibition of PARP-1 preferentially impairs KRAS-mutated intrahepatic cholangiocarcinomas and is mediated by CHK1 kinase</i>	<u>D Castven</u> , F Keggenhoff, S Stojkovic, D Becker, J Castven, C Zimpel, B Straub, T Gerber, H Langer, P Hähnel, T Kindler, J Fahrer, C O Rourke, U Ehmer, A Saborowski, L Ma, X W. Wang, T Gaiser, M Matter, C Sina, S Derer, J Lee, S Roessler, B Kaina, J Andersen, P Galle, J Marquardt	Gold
<i>Refinement of histologic subtypes and identification of biomarkers linked to unfavourable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancement</i>	<u>D Overi</u> , RIR Macías, V Cardinale, L Izquierdo-Sanchez, P Acedo, M Rengo, M Doukas, P Onori, S Leone, B Franceschini, L Di Tommaso, PM Rodrigues, G Torzilli, E Lanza, B Groot Koerkamp, A Garcia Sampedro, SP Pereira, G Grazi, D Alvaro, A Lleo, JM Banales, G Carpino, E Gaudio	Gold
<i>The primary cilium as a tumour-promoting and immunoregulatory organelle in iCCA</i>	<u>S Teles</u> , S Waddell, K Davies, A Rozyczko, K Gournopanos, P Gautier, P Mill, E Jarman, L Boulter	Gold
<i>Usefulness of serum metabolomic profiling for the differential diagnosis in liver cancer: a validation study</i>	<u>K Delgado-Calvo</u> , E Lozano, A Lapitz, J Bustamante, C Alonso, J Bruix, C Cives, L Izquierdo-Sanchez, LM González, L Boix, P Salvador, L Bujanda, L Muñoz-Bellvís, JM Banales, JJG Marin, RIR Macias	Silver Special Recognition
<i>Cancer associated fibroblast plasticity and interaction with the tumour microenvironment in cholangiocarcinoma</i>	<u>A Ravichandra</u> , R Ranjan, V Leone, NB Khaled, R Öllinger, D Hartmann, NH Hüser, R Rad, K Steiger, S Affo, M Reichert	Silver Special Recognition
<i>Advancing next-generation immunotherapy for cholangiocarcinoma</i>	<u>M Yáñez-Bartolomé</u> , Q Serra Camprubí, S Llorente Llorente, EJ Arenas, F Castet, D López Balbuena, M Escorihuela, J Querol, W Oliveros, M Melé, JL Sardina, J Arribas, T Macarulla, TV Tian	Silver Special Recognition

Abstract Title	Authors	Award
<i>Improved cholangiocarcinoma response to chemotherapy through inhibition of MRP3-mediated drug export</i>	<u>M Asensio</u> , O Briz, E Herraiez, R Espinosa-Escudero, L Pérez-Silva, A Peleteiro-Vigil, N Hortelano-Hernandez, O Pötz, LM Gonzalez, O Kadioglu, T Efferth, RIR Macias, J JG Marin, E Lozano	Silver
<i>Cancer stem cell-fibroblast crosstalk regulates the tumor stroma and the tumor immune stroma in intrahepatic cholangiocarcinoma</i>	<u>P Cantallops Vilà</u> , L Sererols Viñas, G Garcia-Vicién, L Chen, A Ravichandra, G Castellano, M Torres-Martin, Q Sun, C Cárcamo Giráldez, S Ariño, L Zanatto, R Martínez García de la Torre, J Ferrer, A Forner, L Boix, M Reig, RF Schwabe, D Sia, P Sancho Bru, S Affò	Silver
<i>Comparison of the tumour microenvironment between early-stage and metastatic biliary tract cancers: analysis of RNAseq data from the BILCAP and I3O-MC-JSBF clinical trials</i>	<u>VE Crolley</u> , R Guest, A Beggs, E Jaynes, S Thorn, J Herrero, I Tomlinson, JW Valle, J Primrose, J Bridgewater	Silver
<i>Transcriptomic landscape of epigenetic effectors in human cholangiocarcinoma</i>	<u>J Elurbide</u> , A Lopez-Pascual, E Valbuena-Goiricelaya, B Castelló-Urbe, E Anaya, JM Herranz, E Adan-Villaescusa, A Irigaray-Miramón, B Sangro, M Arechederra, C Berasain, MG Fernandez-Barrena, MA Avila	Silver
<i>Longitudinal Liquid biopsy in Biliary Tract Cancer patients undergoing first line combination chemotherapy</i>	<u>J Greaves</u> , M Mahdieh, F Amato, C Rae, S Marco, R Casolino, P Sanchon-Sanchez, F Vita, MG Prete, T Nash, A MacMillan, K Allan, P Herzyk, J Galbraith, C Braconi	Silver
<i>Spatial analysis of the complex tumor microenvironment in intrahepatic cholangiocarcinoma</i>	<u>A Makowiecka</u> , C Papazoglou, M Doukas, M Amini, Y Vercoulen, MMA Verstegen	Silver
<i>Novel targeted therapy designed to induce double-strand DNA breaks promotes selective death in naïve and CisPt-resistant cholangiocarcinoma cells</i>	<u>LOlaizola</u> , M Odriozola-Gimeno, M Asensio, P Olaizola, I Rivilla, AR Guimaraes, D de Sancho, X Lopez, PM Rodrigues, FJ Caballero-Camino, E Herraiez, O Briz, L Izquierdo-Sanchez, A Eleta-Lopez, AM Bittner, A Martinez-Amesti, T Miranda, C Braconi, MJ Perugorria, L Bujanda, JGG Marin, FP Cossio, JM Banales	Silver
<i>Establishment of organoids from patient-derived biliary cancer tissue</i>	<u>C Rae</u> , F Amato, C Nixon, G Vlachogiannis, V Cardinale, M Prete, L Rimassa, L Terraciano, L Quinn, H Malik, M Verstegen, B Groot Koerkamp, M Zagnoni, K Paterson, T Kendall, S McHaffie, C McKay, T Elswood, D Kay, E Dickson, M Coates, D Holroyd, F Duthie, D Chang, N Jamieson, C O'Rourke, J Andersen, A Pea, V Corbo, M Fassan, C Braconi	Silver
<i>NOX4/NOX1 dual inhibition in cholangiocarcinoma as an efficient approach to target TGF-beta protumorigenic actions in CAF</i>	<u>J Vaquero</u> , J Amengual, E Gonzalez-Sanchez, M Yañez, L Sererols-Viñas, A Ravichandra, C Guiton, NP Fuste, A Alay, S Hijazo-Pechero, B Martín-Mur, M Gut, A Esteve-Codina, E Ramos, T Serrano, J Ferrer, G Pons, A Mendez-Lucas, S Dooley, GJ Gores, SI Ilyas, M Vallete, L Aoudjehane, L Fouassier, C Coulouarn, S Affo, A Scheiter, D Calvisi, TV Tian, I Fabregat	Silver

Abstract Title	Authors	Award
<i>Dissecting immune cell context to predict response to chemo-immunotherapy in cholangiocarcinoma</i>	<u>R Balsano</u> , T Pressiani, G Milardi, S Bozzarelli, V Zanuso, A Pirozzi, G Tesini, A Lleo, L Rimassa	Bronze
<i>Activation of coagulation factors and impaired fibrinolysis in intrahepatic cholangiocarcinoma</i>	<u>L Fabris</u> , Y Frión-Herrera, C Venturin, M Cadamuro, C Mescoli, U Cillo, E Gringeri, E Campello, P Simioni	Bronze
<i>Adherence to Enhanced Recovery After Surgery (ERAS) Protocol in Pancreaticoduodenectomy Surgery Applied for the Treatment of Cholangiocarcinoma: A Case Report</i>	<u>E Gökçe</u> , B Ügü	Bronze
<i>Cholangiocarcinoma in Latin America: A Multicenter Observational Study Alerts on Ethnical Disparities in Tumor Presentation and Outcome</i>	<u>L Izquierdo-Sanchez</u> , LG da Fonseca, PH Hashizume, Y Carlino, E Liza Baca, C Zambrano, S Sepulveda, A Bolomo, PM Rodrigues, I Riaño, A Boonstra, JD Debes, L Bujanda, FJ Carrilho, M Arrese, JC Roa, E Carrera, J Díaz Ferrer, D Balderramo, CP Oliveira, JM Banales	Bronze
<i>GENTLE: Clinical implications of GENomic profile in biliary Tract cancer patients undergoing chemotherapy/immunotherapy treatment.</i>	<u>S McHaffie</u> , F Amato, T Kendall, C Braconi	Bronze
<i>Systemic therapy is more important than local therapy in the palliation of inoperable perihilar cholangiocarcinoma: results from a single-center randomized control trial (COMBO-RFA)</i>	<u>M Birligea</u> , C Diaconu, A Bengus, A Voiosu, C Popp, B Galateanu, O Ginghamina, B Mateescu, T Voiosu	Bronze
<i>A Contrastive Learning Approach to Multimodal Biliary Cancer Data Integration</i>	<u>J Oliveira</u> , P Ramos	Bronze
<i>Investigating the Impact of Somatic Mutations on Transcription Factor Binding Sites in Biliary Tract Cancer</i>	<u>B Otlu</u> , H Hilmi Kılınc	Bronze
<i>Unraveling fibroinflammatory and immune signatures in PSC and CCA by spatial multiomics</i>	<u>D Parra Sánchez</u> , A García-Sampedro, SP Pereira, P Acedo	Bronze
<i>Role of the splicing factor PCBP2 in cholangiocarcinoma malignancy and chemoresistance</i>	Maria Reviejo, Maitane Asensio, Elisa Lozano, Pilar Acedo, Rebeca P. Marijuan, Marta R. Romero, Oscar Briz, Rocio I.R. Macias, Jose J.G. Marin	Bronze
<i>RORA agonism reduces tumor cell proliferation and desmoplasia in intrahepatic cholangiocarcinoma</i>	<u>L Sererols Viñas</u> , A Lapitz, RA Martínez-García de la Torre, P Cantallops Vilà, S Ariño, G Garcia-Vicién, C Cárcamo Giráldez, J Ferrer, A Forner, L Boix, M Reig, PM Rodrigues, JM Bañales, P Sancho-Bru, S Affò	Bronze

Abstract Title	Authors	Award
<i>Primary biliary cholangitis symptoms are reduced in liver specific Mcpip1 knock-out mice after treatment with Lactobacillus rhamnosus</i>	K Trzos , T Hutsch, G Machaj, G Ylla, J Jura, J Kotlinowski	Bronze
<i>Discovery of Potential Inhibitors for Ribonucleotide Reductase Enzyme in Biliary Tract Cancer: Insights from Molecular Modelling Studies</i>	Ercument Yilmaz, Zeynep Dilan Turgut, Gizem Tatar Yilmaz	Bronze
<i>Fluid flow dynamics within an organ-on-a-chip model: numerical assessment and experimental validation</i>	V Carvalho , IM Gonçalves, N Rodrigues, P Sousa, V Pinto, G Minas, H Kaji, S Shin, RO Rodrigues, SFCF Teixeira, RA Lima	Selection
<i>Cannabinoids for cancer-associated symptoms: a systematic review and meta-analysis</i>	I Creangă-Murariu , I Rezuş, R Karami, A Rancz, D Sándor Veres, MA Engh, M Obeidat, S Bunduc, T Alexa-Stratulat, B Tamba, P Hegyi	Selection
<i>Identification of unique peripheral blood mononuclear cell and exosomal mRNA signatures for the early detection of cholangiocarcinoma</i>	K Fraser , P Acedo, SP Pereira	Selection
<i>Intelligent Computation Technique Based Bile Duct Cancer Diagnosis</i>	D Kaya , T Kaya	Selection
<i>Analysis of Metallothionein in Patients with Pancreatic Cancer / Luděk Melich</i>	L Melich , J Werle, M Fořtová, L Vysloužilová, K Kotaška, E Klapková, O Štěpánková, J Čepová, R Průša, R Kizek	Selection
<i>Computer-aided drug design of dual PI3K/HDAC inhibitors in search for innovative therapy of cancer</i>	K Nikolic , M Beljkas, E Kukic, and S Oljadic	Selection
<i>Clinical characteristics and outcomes of patients with intrahepatic cholangiocarcinoma and underlying liver disease</i>	G Tesini , V Zanuso, A Pirozzi, E Valenzi, R Balsano, T Pressiani, S Bozzarelli, L Rimassa	Selection
<i>Tumor Biology, Treatment Patterns, and Survival Outcomes in Young-onset Biliary Tract Cancers</i>	A Turpin , T Pudlarz, L Antoun, N Tissera, M Hilmi, F Castet, D López-Valbuena, M Delaye, A Italiano, M Valéry, V Boige, D Malka, E García-Galea, G Castillo, TV Tian, A Hollebecque, C Smolenschi, M Ducreux, T Macarulla, A Boilève	Selection
<i>Onset of symptom prior to diagnosis of pancreatic and biliary tract cancer – identification of areas of unmet needs for early diagnosis</i>	A Martirena , C Santomá Saladich, E Ruiz Hispán, R Fuentes Mateos, A Lamarca	Selection